| 產品編號 | bs-4076R-Gold |
| 英文名稱 | Rabbit Anti-phospho-E2F1 (Ser364)/Gold Conjugated antibody |
| 中文名稱 | 膠體金標記的磷酸化轉錄因子E2F-1抗體 |
| 別 名 | E2F1 (phospho S364); E2F1 (phospho Ser364); p-E2F1 (S364); p-E2F1 (Ser364); E2F 1; E2F transcription factor 1; E2F-1; E2f1 E2F transcription factor 1; KIAA4009; mKIAA4009; OTTHUMP00000030661; PBR 3; PBR3; PRB binding protein E2F 1; PRB-binding protein E2F-1; RBAP 1; RBAP-1; RBAP1; RBBP 3; RBBP-3; RBBP3; RBP 3; RBP3; Retinoblastoma associated protein 1; Retinoblastoma binding protein 3; Retinoblastoma-associated protein 1; Retinoblastoma-binding protein 3; Transcription factor E2F1; E2F1_HUMAN. |
| 規格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul（10nm 15nm 35nm） |
| 產品類型 | 磷酸化抗體 |
| 研究領域 | 腫瘤 細胞生物 免疫學 轉錄調節因子 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Human, (predicted: Mouse, Rat, ) |
| 產品應用 | IEM=1:20-200 ICA=1:20-200 ChIP=1:20-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 48kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 0.4mg/ml |
| 免 疫 原 | KLH conjugated Synthesised phosphopeptide derived from human E2F1 around the phosphorylation site of Ser364 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.02M TBS(pH8.2) with 1% BSA, 0.03% Proclin300. |
| 保存條件 | Store at 2-8 oC for 3-6 months. Avoid repeated freeze/thaw cycles. |
| 產品介紹 |
background: E2F's are DNA binding proteins, which associate with negative regulators, such as the retinoblastoma p107 protein, resulting in an altered rate of gene transcription. The E2F proteins contain several evolutionally conserved domains found in most members of the family. These domains include a DNA binding domain, a dimerization domain which determines interaction with the differentiation regulated transcription factor proteins (DP), a transactivation domain enriched in acidic amino acids, and a tumor suppressor protein association domain which is embedded within the transactivation domain. This protein and another 2 members, E2F2 and E2F3, have an additional cyclin binding domain. E2F1 is proposed to be involved in several cellular processes that range from tumor suppressor, cell progression and oncogenesis. E2F1 overexpression can also drive cells into apoptosis. Subunit: Component of the DRTF1/E2F transcription factor complex. Forms heterodimers with DP family members. The E2F-1 complex binds specifically hypophosphorylated retinoblastoma protein RB1. During the cell cycle, RB1 becomes phosphorylated in mid-to-late G1 phase, detaches from the DRTF1/E2F complex, rendering E2F transcriptionally active. Viral oncoproteins, notably E1A, T-antigen and HPV E7, are capable of sequestering RB protein, thus releasing the active complex. Interacts with TRRAP, which probably mediates its interaction with histone acetyltransferase complexes, leading to transcription activation. Binds TOPBP1 and EAPP. Interacts with ARID3A. Interacts with TRIM28; the interaction inhibits E2F1 acetylation through recruiting HDAC1 and represses its transcriptional activity. Interaction with KAT2B; the interaction acetylates E2F1 enhancing its DNA-binding and transcriptional activity. Interacts with BIRC2/c-IAP1 (via BIR domains). Interacts with human cytomegalovirus/HHV-5 protein UL123. Subcellular Location: Nucleus. Post-translational modifications: Phosphorylated by CDK2 and cyclin A-CDK2 in the S-phase. Similarity: Belongs to the E2F/DP family. Database links: Entrez Gene: 1869 Human Entrez Gene: 13555 Mouse Omim: 189971 Human SwissProt: Q01094 Human SwissProt: Q61501 Mouse Unigene: 654393 Human Unigene: 18036 Mouse Unigene: 72471 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. E2F1—屬于調節性轉錄因子E2F家族。有學者認為：E2F-1既可作為癌基因起作用，又可作為抑癌基因起作用。其不同可能由細胞中其他生長促進或抑制性蛋白質水平和（或）活性決定，同時與細胞所處環境及器官特異性有關。在控制細胞周期和腫瘤抑制基因蛋白的活性方面起關鍵作用。 |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
